Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascentage Pharma Group International Unsponsored ADR ( (AAPG) ) has issued an update.
On May 12, 2026, Ascentage Pharma Group International, a global biopharmaceutical company specializing in innovative oncology therapies, announced that 17 clinical advances from its core assets will be showcased at the 31st European Hematology Association Congress in Stockholm from June 11 to 14, 2026. The accepted abstracts span ongoing studies of Olverembatinib, China’s first approved third-generation BCR-ABL inhibitor, and Lisaftoclax, a China-developed Bcl-2 selective inhibitor, underscoring the company’s growing presence in hematology research.
Highlighted presentations include updated efficacy and safety data on Olverembatinib as a second-line therapy in chronic-phase CML, its performance in patients resistant to prior ponatinib or asciminib with ASXL1 mutations, and new results from the global Phase 3 POLARIS-1 trial in newly diagnosed Ph+ ALL. Additional data on Lisaftoclax, including prognostic correlations in a pivotal Phase 2 CLL/SLL study and a Phase 1b pediatric trial combining Olverembatinib and Lisaftoclax in relapsed or refractory Ph+ ALL, point to potential expansion of Ascentage’s clinical footprint in both adult and pediatric hematologic malignancies, although both agents remain investigative in the U.S.
The most recent analyst rating on (AAPG) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.
Spark’s Take on AAPG Stock
According to Spark, TipRanks’ AI Analyst, AAPG is a Underperform.
The score is primarily constrained by weak financial performance driven by persistent and worsening losses and significant cash burn, despite strong revenue growth and high gross margins. Technicals also reflect a weak trend with negative momentum. Valuation is further pressured by a negative P/E and no dividend yield data.
To see Spark’s full report on AAPG stock, click here.
More about Ascentage Pharma Group International Unsponsored ADR
Ascentage Pharma Group International is a global, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapies for cancer and other diseases. Its pipeline centers on inhibitors of key apoptotic pathway proteins such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders, with strategic partnerships spanning major multinational drugmakers and leading research institutions.
The company’s first approved product, Olverembatinib, is China’s first novel third-generation BCR-ABL1 inhibitor for certain chronic myeloid leukemia (CML) indications and is included on the National Reimbursement Drug List. Its second approved product, Lisaftoclax, is a Bcl-2 inhibitor cleared in China for previously treated CLL/SLL patients, and both drugs are being advanced in multiple global registrational Phase III trials across leukemias, lymphomas, AML, MDS and SDH-deficient GIST, reflecting Ascentage’s push for broader international market penetration.
Average Trading Volume: 3,253
Technical Sentiment Signal: Sell
Current Market Cap: $2B
Find detailed analytics on AAPG stock on TipRanks’ Stock Analysis page.